Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients

Background. Hematopoietic cell transplant (HCT) recipients who develop coronavirus disease 2019 (COVID-19), have dismal prognosis with approximately 20% mortality. Given the lack of a specific and effective therapy, the availability of various vaccination platforms against SARS-CοV-2 has generated o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriilaki, Eleni, Papadopoulou, Anastasia, Touloumenidou, Tasoula, Stavridou, Fani, Koravou, Evdoxia, Giannaki, Maria, Papalexandri, Apostolia, Karavalakis, Georgios, Batsis, Ioannis, Kourelis, Andreas, Chatzopoulou, Fani, Chatzidimitriou, Dimitrios, Sotiropoulos, Damianos, Yannaki, Evangelia, Sakellari, Ioanna, Anagnostopoulos, Achilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701499/
http://dx.doi.org/10.1182/blood-2021-149399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701499/
http://dx.doi.org/10.1182/blood-2021-149399

Ejemplares similares